Marksans Pharma recalls Metformin ER Tablets over probable carcinogen
Metformin extended release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus
New Delhi: Marksans Pharma on Monday said it is recalling 11,279 bottles of diabetes drug Metformin extended release tablets due to presence of cancer causing contaminant.
The company has issued a voluntary recall of one batch of Metformin extended release tablets (USP 500 mg) due to detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.
The recalled batch contains 11,279 bottles, it added. Metformin extended release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.
Read also: 5 firms told to recall Metformin for high levels of probable carcinogen
Next Story
